AlloMap’s Medicare reimbursement to increase in 2018
CareDx, Inc. (CDNA)
Last caredx, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.caredxinc.com
Company Research
Source: GlobeNewswire
BRISBANE, Calif., Sept. 22, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Medicare reimbursement for AlloMap will increase from its current level of $2,840.75 to $3,240. Medicare released the preliminary 2018 Clinical Laboratory Fee Schedule (CLFS) reflecting a 14% increase to CPT 81595, the code that represents AlloMap. The increase is the result of the Protecting Access to Medicare Act (PAMA) of 2014. PAMA revises the Medicare payment system for clinical laboratory tests by setting Medicare payments based on the weighted median of rates paid by private payers. Effective January 1, 2018, Medicare plans to reimburse CareDx $3,240 for AlloMap testing of Medicare beneficiaries. “The updated clinical laboratory test rate reflects the value that AlloMap brings to transplant patient
Show less
Read more
Impact Snapshot
Event Time:
CDNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDNA alerts
High impacting CareDx, Inc. news events
Weekly update
A roundup of the hottest topics
CDNA
News
- CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Business Wire
- CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last? [Yahoo! Finance]Yahoo! Finance
- CareDx, Inc (NASDAQ: CDNA) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $15.00 price target on the stock.MarketBeat
- CareDx Appoints John W. Hanna as its New President and Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
CDNA
Earnings
- 2/28/24 - Beat
CDNA
Sec Filings
- 4/16/24 - Form 8-K
- 4/10/24 - Form 4
- 4/9/24 - Form 4/A
- CDNA's page on the SEC website